主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE ›› 2021, Vol. 44 ›› Issue (1): 60-68.doi: 10.3969/j.issn.1006-2157.2021.01.010

• Chinese Medicinal Pharmacology • Previous Articles     Next Articles

Using network pharmacology to study the molecular mechanism and validate the key pathway of Kidney-qi pill against Type 2 diabetes mellitus*

Yang Jinwei1, Yu Rong2,3, Wu Yongjun4, Liu Xiu3, Deng Yihui1#   

  1. 1 College of Integrated Traditional Chinese and Western Medicine,Hunan University of Chinese Medicine,Changsha,Hunan 410208,China;
    2 Graduate School,Hunan University of Chinese Medicine,Changsha,Hunan 410208,China;
    3 Key Laboratory of Colleges and Universities,Traditional Chinese Medicine Prescription and Transformation of Medical Laboratory,Changsha,Hunan 410208,China;
    4 School of pharmacy,Hunan University of Chinese Medicine,Changsha,Hunan 410208,China
  • Received:2020-07-29 Online:2021-01-30 Published:2021-01-18
  • Contact: Prof.Deng Yihui,Ph.D,Doctoral Supervisor.College of Integrated Traditional Chinese and Western Medicine,Hunan University of Chinese Medicine.No.300,Xueshi Road,Hanpu Science and Education Park,Yuelu District,Changsha,Hunan 410208.E-mail:644138330@qq.com.
  • Supported by:
    National Natural Science Foundation of China(No. 81573956),National Key Research and Development Plan of China(No.2018 YFC1704300),Graduate Research Innovation Project of Hunan province(No. CX2018B471),Open Fund for Traditional Chinese Medicine of Hunan Province(No.2018ZYX44)

Abstract: Objective To explore the active components,core targets and mechanism of Kidney-qi Pill in treating for Type 2 diabetes mellitus (T2DM),based on network pharmacology and preliminarily verify it through in vitro experiment.Methods The TCM database@Taiwan,Chemistry Database and TCMSP database were used to filter the chemical composition and target of Kidney-qi pill.The corresponding gene name of each target was obtained in UniProt database.Then,the target genes of Kidney-qi pill and T2DM were plotted,depending on the relationship between chemical composition and target.The String software was used to construct Kidney-qi pill ingredients-targets network.The DAVID database was used to analyze the pathway enrichment of the interaction gene,and core signaling pathways were performed by using KEGG pathway analysis tool.Insulinoma cell line INS-1 cells in rats were used to establish damage model by using high concentration of glucose.SD rats were administered intragastrically with 8.64 g/kg Kidney-qi pill to prepare medicated plasma,which was then extracted for INS-1 cells experiment.The growth inhibition was tested by using CCK-8 essay.Key signal pathways were validated by using Western blot assay.Results 58 chemical composition of Kidney-qi pill were analyzed.A total of 198 human target genes related to T2DM were obtained.The network analysis indicated that Kidney-qi pill can treat T2DM by regulating AKT1,JUN,TNF and PTGS2 targets,involving phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT) signaling pathway,mitogen-activated protein kinase (MAPK) signaling pathway,tumor necrosis factor (TNF) signaling pathway,Neuroactive ligand-receptor interaction and hypoxia inducible factor-1(HIF-1) signaling pathway.Kidney-qi pill medicated plasma significantly promoted the proliferation of INS-1 cells,and apparently increased the expression of PI3K,AKT and p-AKT (P<0.01).There was no significant difference in Kidney-qi pill medicated plasma group and 740 Y-P group (P>0.05). Conclusion Conclusion Kidney-qi pill contains herbs of the same or different active ingredients,and this prescription can effectively treat T2DM.Based on the network pharmacology,Kidney-qi pill can promote cell signal transduction,regulate mitochondrial function and energy metabolism.The experiments have confirmed that Kidney-qi pill can affect the expression of PI3K/ AKT pathway related proteins.This research can provide theoretical basis for further experiments and clinical application.

Key words: Kidney-qi pill, network pharmacology, type 2 diabetes mellitus, potential target, rats, INS-1 cells

CLC Number: 

  • R285.5